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Background: Germline mutations in PALB2 have been identified in approximately 1% of familial breast cancer (BC) in
several populations. Nevertheless its contribution in the South-American population is unknown. The goal of this study
was to determine the prevalence of PALB2 mutations in the Chilean population.
Methods: 100 Chilean BRCA1/2-negatives familial BC cases were included for the PALB2 mutation analysis. We use
conformational sensitive gel electrophoresis and direct sequencing. Using a case-control design, we studied the
identified variants in 436 BC cases and 809 controls to evaluate their possible association with BC risk.
Results: No pathogenic mutations were detected. We identified three variants, the variant c.1861C > A not
previously described was found in one of the 436 cases and none of the 809 controls. The bioinformatic
analyses indicate that this variant probably is not pathogenic. PALB2 c.1676A > G (rs152451A/G) and c.2993C > T
(rs45551636C/T) variants were significantly associated with increased BC risk only in cases with a strong family
history of BC (OR = 1.9 [CI 95% 1.3-2.8] p < 0.01 and OR = 3.3 [CI 95% 1.4-7.3] p < 0.01, respectively). The
rs152451A/G-rs45551636C/T composite genotype produce increase of the BC risk in cases with a strong family
history of BC (OR = 3.6 [CI 95% 1.7-8.0] p = 0.003). The rs152451-G/rs45551636-C and rs152451-G/rs45551636-T
haplotypes were associated with an increased BC risk only in cases with a strong family history of BC (OR = 1.6
[CI 95% 1.0-2.5] p = 0.05 and OR = 3.7 [CI 95% 1.8-7.5] p < 0.001, respectively).
Conclusion: Our results suggest that PALB2 c.1676A > G and c.2993C > T play roles in BC risk in women with a
strong family history of BC.
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Genetic factors play an important role in breast cancer
(BC) development, including the presence of BRCA1,
BRCA2, ATM, and other genes [1], but only 5% of BC
incidence can be explained by mutation in these high-
penetrance genes [2]. Moreover, these genes are respon-
sible for only about 16-20% of the risk for familial BC.
Therefore, the genetic basis of 80% of familial cases re-
mains unexplained [3]. The remaining risk is likely to* Correspondence: ljara@med.uchile.cl
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susceptibility genes.
The PALB2 (partner and localizer of BRCA2) protein
interacts with BRCA2, stabilizing the intranuclear accu-
mulation of BRCA2 proteins at sites of DNA damage
[4]. PALB2 is also recruited by BRCA1 in response to
DNA damage and serves as a linker between BRCA1 and
BRCA2, necessary for BRCA2-mediated homologous-
recombination repair [5,6]. Thus, BRCA1, BRCA2, and
PALB2 are key BC susceptibility genes that function
together in the same DNA damage response pathway
[5,7]. Biallelic loss of PALB2 causes increased predispositionThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,




Three or more family members with breast and/or
ovarian cancer
124 (28.4%)
Two family members with breast and/or ovarian cancer 149 (34.2%)
Single affected individual with breast cancer≤ age 35 84 (19.3%)
Single affected individual with breast cancer between
age 36 and 50
79 (18.1%)
TOTAL 436 (100%)
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and Fanconi anemia [8].
Germline PALB2 mutations are rare, but have been as-
sociated with increased risk for breast and other cancers.
In families with multiple breast cancer cases, germline
PALB2 mutations have been reported in populations
from Western Europe, the United Kingdom, Finland,
French Canada, and Australia [9-12]. In familial BC,
germline PALB2 mutations are associated with a 2.3- to
6.0-fold increased risk for BC [9,13,14]. Germline PALB2
mutations have also [13] been reported in a lower fre-
quency in unselected female BC cases from Finland,
French Canada, Australia, China, Malaysia, and Singapore
[10-12,15,16]. No PALB2 mutations have been identified
in Jewish families of either Ashkenazi or non-Ashkenazi
origin [17,18]. The contribution of PALB2 mutations to
BC in the South American population is unknown. The
Chilean population is the result of admixture between
Asian and Spanish populations; therefore, whether germ-
line PALB2 mutations contribute to Chilean BC risk is
unknown.
In this study, we screened the coding regions and exon-
intron boundaries of the PALB2 gene in BRCA1/2-negative
women with familial BC, to determine the contribution of
PALB2 variation in the Chilean population. Also, using
a case-control design, we studied the c.1676A > G
(exon 4), c.1861C > A (exon 5), and c.2993C > T (exon




A total of 436 BC patients belonging to 436 high-risk
BRCA1/2-negative Chilean families were selected from
the files of the Servicio de Salud del Area Metropolitana
de Santiago, Corporación Nacional del Cáncer (CONAC)
and other private services in the Metropolitan Area of
Santiago. All index cases were tested for BRCA1 and
BRCA2 mutations as described [19]. Pedigrees were
constructed on the basis of an index case considered
to have the highest probability of being a deleterious
mutation carrier. None of the families met the strict
criteria for other known syndromes involving BC, such
as Li-Fraumeni, ataxia-telangiectasia, or Cowden disease.
Table 1 shows the specific characteristics of the fam-
ilies selected according to the inclusion criteria. All fam-
ilies participating in the study self-reported Chilean
ancestry dating from several generations, after extensive
interviews with several members of each family from dif-
ferent generations. In the selected families, 12.4% (54/
436) had cases of bilateral BC; 8.0% (35/436) had cases
of both BC and ovarian cancer (OC); and 2.1% (9/436)
had male BC. In the BC group, the mean age of diagno-
sis was 42.7 years, and 75.2% had age of onset < 50 years.This study was approved by the Institutional Review
Board of the School of Medicine of the University of Chile.
Informed consent was obtained from all participants.
Control population
The sample of healthy Chilean controls (n = 809) was re-
cruited from CONAC files. DNA samples were taken
from unrelated individuals with no personal or familial
history of cancer who gave their consent for anonymous
testing. These individuals were interviewed and in-
formed as to the aims of the study. DNA samples were
obtained according to all ethical and legal requirements.
The control sample was matched by age and socioeco-
nomic strata with respect to the cases. Over 90% of cases
and controls lived in the city of Santiago.
Mutation analysis
Genomic DNA was extracted from peripheral blood
lymphocytes of 436 cases belonging to the high-risk se-
lected families and 809 controls. Samples were obtained
according to the method described by Chomczynski and
Sacchi [20].
PALB2 complete sequence analysis
This analysis was performed in 100 cases belonging to
families with a) three or more family members with
breast and/or ovarian cancer and b) two family members
with breast and/or ovarian cancer. The whole coding se-
quence and exon–intron boundaries of the PALB2 gene
were amplified by polymerase chain reaction (PCR)
using previously-described primers [21]. For exon 9, we
designed primers using Web Primer3 version 0.4.0 [22].
We amplified 16 amplicons, whose sizes are shown in
Additional file 1: Table S1. The fragments obtained were
analyzed for sequence variants using conformational
sensitive gel electrophoresis (CSGE) [23]. Amplified sam-
ples were denaturated at 95°C for 5 minutes and 65°C for
30 minutes to generate heteroduplex. The products were
diluted 1:2 in sucrose buffer and loaded in a partially de-
naturing MDE® gel (Cambrex, UK) at constant power of
7 W during different time periods depending on the size
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vacuum gel dryer.
Any fragment showing a mobility shift was directly se-
quenced, to identify the variant. Sequencing was per-
formed in an ABI 3730XL automated fluorescence-based
cycle sequencer and a BigDye v.3.1 terminator system
(Applied Biosystems, Foster City, CA). The sequences uti-
lized for naming PALB2 sequence variants, obtained from
the NCBI RefSeq database, were NM_024675.3 (tran-
script) and NP_078951.2 (protein).
PALB2 rs152451 (1676A > G), rs45551636 (2993C > T), and
c. 1861C > A analysis
Genotyping for rs152451 (c.1679A > G), rs45551636
(c.2993C > T), and c.1861C > A was carried out using
TaqMan SNP Genotyping Assays (Applied Biosystems,
Foster City, CA) (assay ID C_2392113_10, C_86371270_10,
and a customized assay, respectively). The reaction was per-
formed in a 10 uL final volume containing 5 ng of genomic
DNA, 1X TaqMan Genotyping Master Mix, and 1X Taq-
Man SNP Genotyping Assay. Polymerase chain reaction
was carried out in a StepOnePlus Real-Time PCR System
(Applied Biosystems, Foster City, CA). The thermal cycles
were initiated for 10 minutes at 95°C, followed by 40 cycles
each of 92°C for 15 seconds and 60°C for 1 minute. Each
genotyping run contained DNA controls confirmed by se-
quencing. The alleles were assigned using the SDS 2.2 soft-
ware (Applied Biosystems, Foster City, CA). As a quality
control, we repeated the genotyping on ~10% of the sam-
ples, and all genotype scoring was performed and checked
separately by two reviewers unaware of the case-control
status.
Bioinformatics and statistical analyses
The Hardy-Weinberg equilibrium assumption was assessed
in the control sample using a goodness-of-fit chi-square
test (HWChisq function included on “HardyWeinberg”.
package v.1.4.1). Fisher’s exact test was used to test the as-
sociation of genotypes and/or alleles between cases and
controls. p < 0.05 was used as the criterion of significance.
The odds ratios (OR) and their 95% confidence interval
(CI) were calculated to estimate the strength of the associ-
ation between cases and controls (odds ratio fisher func-
tion included on “epitools” package v.0.5-6). Haplotype
estimation was carried out using UNPHASED v.3.1.5 soft-
ware, which uses a maximum likelihood approach [24]. In
silico analyses of the effect of missense mutations on pro-
tein function were carried out using PolyPhen-2 (Poly-
morphism Phenotyping version 2) [25], SIFT [26] and
PROVEAN [27]. To evaluate protein stability we used I-
Mutant 3.0 tools (http://gpcr2.biocomp.unibo.it/cgi/predic-
tors/I-Mutant3.0/I-Mutant3.0.cgi). We obtained the wild-
type structure of the PALB2 protein from RASMOL
(http://rasmol.org/) and used MODELLER v.9.12 (http://salilab.org/modeller/) to analyze the 3D-structure and
function of the PALB2 protein.Results
We analyzed the complete coding sequence and splice-
boundary region of PALB2 in 100 probands from BC
families negative for BRCA1 and BRCA2 point mutations
with the aim of identifying PALB2 sequence variation in a
Chilean population. We identified three sequence variants:
c.1676A >G (p.Q559R, rs152451) (exon 4), c.1861C>A
(p.P621M) (exon 5), and c.2993C>T (p.G998E, rs45551636)
(exon 9). The variants detected were analyzed in 436 BC
BRCA1/2-negative cases and 809 controls. For the analysis,
the whole sample was subdivided into two groups: cases
belonging to families with two or more family members with
BC and/or OC (n = 273) (subgroup A) and non-familial
early-onset BC (≤50 years) (n = 163) (subgroup B).
The variant c. 1861C > A, not previously described in
the literature nor in the PALB2 variation database
(http://www.lovd.nl/PALB2), was found in only one of
the 436 cases and none of the 809 controls. Therefore,
this mutation corresponds to a new mutation not pre-
viously described.
The c.1676A >G and c.2993C > T variants correspond to
previously-described variants (rs152451 and rs45551636,
respectively). Table 2 shows the genotype distributions and
allele frequencies of rs152451 and rs45551636 variants in
the whole data set and in subgroups A and B with respect
to the controls. The observed genotype frequencies for
the two variants were all in Hardy–Weinberg equilib-
rium in the controls (P = 0.46 for rs152451, P = 0.68 for
rs45551636, respectively).
In the single locus analysis, the genotype and allele
distribution for rs152451 did not indicate an association
of this variant with increased BC risk either in the whole
sample or in subgroup B. However, in the familial BC
cases (subgroup A), the minor allele frequency (MAF)
(allele G) was higher in cases than in controls (0.12 and
0.09, respectively, p = 0.03). Furthermore, in subgroup A,
allele G carriers (AG + GG) were associated with a sig-
nificantly increased BC risk (OR = 1.5 [CI 95% 1.1-2.1],
p = 0.02) (Table 2). We also analyzed the relationship
between rs152451 and BC risk within patients with BC
familial history according the number of BC cases in the
family (Table 3). No association between rs152451 and
BC risk was found in cases belonging to families with
two BC and/or OC cases. Nevertheless, BC risk was signifi-
cantly increased in cases belonging to families with 3 or
more members affected by BC and/or OC. In these families,
the frequency of allele G was 0.16 in BC cases versus 0.09 in
controls (OR= 1.9 [CI 95% 1.3-2.8] p < 0.01), and G allele
carriers (AG and AG+GG) were associated with a signifi-
cantly increased BC risk (OR= 2.0 [CI 95% 1.3-3.2] p < 0.01).
Table 2 Genotype and allelic frequencies of PALB2 rs152451 and rs45551636 in BRCA1/2-negative breast cancer cases
and controls
All BC cases (n = 436) Families with ≥ 2 BC and/or OC
cases (n = 273)






BC cases (%) P valuea OR [95% CI] BC cases (%) P valuea OR [95% CI] BC cases (%) P valuea OR [95% CI]
rs152451
AA 674 (83.3%) 351 (80.5%) - 1.0 (ref) 210 (76.9%) 0 1.0 (ref) 141 (86.5%) - 1.0 (ref)
AG 127 (15.7%) 79 (18.1%) 0.26 1.2 [0.9-1.6] 60 (22.0%) 0.02 1.5 [1.1-2.2] 19 (11.7%) 0.23 0.7 [0.4-1.2]
GG 8 (1.0%) 6 (1.4%) 0.57 1.4 [0.4-4.8] 3 (1.1%) 0.73 1.2 [0.2-5.1] 3 (1.8%) 0.41 1.8 [0.3-7.6]
AG + GG 135 (16.7%) 85 (19.5%) 0.21 1.2 [0.9-1.6] 63 (23.1%) 0.02 1.5 [1.1-2.1] 22 (13.5%) 0.35 0.8 [0.5-1.3]
A 1475 (0.91) 781 (0.90) - 1.0 (ref) 480 (0.88) 0 1.0 (ref) 301 (0.92) - 1.0 (ref)
G 143 (0.09) 91 (0.10) 0.19 1.2 [0.9-1.6] 66 (0.12) 0.03 1.4 [1.0-1.9] 25 (0.08) 0.59 0.9 [0.5-1.3]
rs45551636
CC 786 (97.2%) 413 (94.7%) - 1.0 (ref) 255 (93.4%) - 1.0 (ref) 158 (96.9%) - 1.0 (ref)
CT 23 (2.8%) 22 (5.0%) 0.06 1.8 [1.0-3.5] 17 (6.2%) 0.01 2.3 [1.1-4.5] 5 (3.1%) 0.80 1.1 [0.3-2.3]
TT 0 (0.0%) 1 (0.2%) - - 1 (0.4%) - 0 0 (0.0%) - -
CT + TT 23 (2.8%) 23 (5.2%) 0.04 1.9 [1.0-3.6] 18 (6.6%) 0.01 2.4 [1.2-4.7] 5 (3.1%) 0.80 1.1 [0.3-2.3]
C 1595 (0.99) 848 (0.97) - 1.0 (ref) 527 (0.97) - 1.0 (ref) 321 (0.98) - 1.0 (ref)
T 23 (0.01) 24 (0.03) 0.03 2.0 [1.1-3.7] 19 (0.03) 0.01 2.5 [1.3-4.8] 5 (0.02) 0.80 1.1 [0.3-2.9]
BC breast cancer, OC ovarian cancer, OR odds ratio, CI confidence interval.
aFisher’s exact test.
Bold values are statistically significant (P < 0.05).
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tribution did not indicate an association of this variant
with non-familial early-onset BC (≤50 years) (Table 2).
Nevertheless, in the whole sample, the MAF (T allele) was
higher in cases (0.03) than controls (0.01), and theTable 3 Genotype and allelic frequencies of PALB2 rs152451
families in BRCA1/2-negative breast cancer cases and controls
Families with 2 BC and/or O
Genotype or allele Controls (%) (n = 809) BC cases (%) P valuea
rs152451
AA 674 (83.3%) 88 (71.0%) -
AG 127 (15.7%) 33 (26.6%) 0.47
GG 8 (1.0%) 3 (2.4%) -
AG + GG 135 (16.7%) 36 (29.0%) 0.63
A 1475 (0.91) 209 (0.84) -
G 143 (0.09) 39 (0.16) 0.91
rs45551636
CC 786 (97.2%) 113 (91.1%) -
CT 23 (2.8%) 10 (8.1%) 0.30
TT 0 (0.0%) 1 (0.8%) -
CT + TT 23 (2.8%) 11 (8.9%) 0.30
C 1595 (0.99) 236 (0.95) -
T 23 (0.01) 12 (0.05) 0.30
BC breast cancer, OC ovarian cancer, OR odds ratio, CI confidence interval.
aFisher’s exact test.
Bold values are statistically significant (P < 0.05).difference was statically significant (OR = 2.0 [CI 95%
1.1-3.7], p = 0.03). This result indicates that the T allele
is associated with a significantly increased BC risk. We
also observed increased risk of BC for T allele carriers
(CT + TT) in the whole sample and in subgroup Aand rs45551636 according the number of BC cases in the
C cases (n = 124) Families with ≥ 3 BC and/or OC cases (n = 149)
OR [95% CI] BC cases (%) P valuea OR [95% CI]
1.0 (ref) 122 (81.9%) - 1.0 (ref)
1.2 [0.7-1.9] 27 (18.1%) <0.01 2.0 [1.2-3.1]
- 0 (0.0%) 0.13 2.9 [0.5-12.2]
1.1 [0.7-1.8] 27 (18.1%) <0.01 2.0 [1.3-3.2]
1.0 (ref) 271 (0.91) - 1.0 (ref)
1.0 [0.6-1.6] 27 (0.09) <0.01 1.9 [1.3-2.8]
1.0 (ref) 142 (95.3%) - 1.0 (ref)
1.7 [0.6-4.1] 7 (4.7%) <0.01 3.0 [1.2-6.8]
- 0 (0.0%) - -
1.7 [0.6-4.1] 7 (4.7%) <0.01 3.3 [1.4-7.3]
1.0 (ref) 291 (0.98) 0 1.0 (ref)
1.7 [0.6-4.1] 7 (0.02) <0.01 3.5 [1.6-7.5]
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95% 1.2-4.7] p = 0.01, respectively) (Table 2). When we
analyze the effect of allele T considering the number of
BC cases in the families, no association between
rs45551636 and BC risk was found in cases belonging
to families with two BC cases. Nevertheless, BC risk
increased 3.0-fold in the heterozygous group (OR = 3.0
[CI 95% 1.2-6.8] p < 0.01) and 3.3-fold in allele T carriers
(CT +TT) belonging to families with 3 or more cases of
BC (OR = 3.3 [CI 95% 1.4-7.3] p < 0.01) (Table 3).
Table 4 shows the composite genotype analysis for
rs152451 and rs45551636. The rs152451 A/G - rs45551636
C/T composite genotype showed a higher frequency in
cases compared to controls in the whole sample and in
subgroup A (OR = 1.9 [CI 95% 1.0–3.6] p = 0.04 and OR =
2.6 [CI 95% 1.4–4.5] p = 0.01 respectively) (Table 4). Never-
theless, the frequency of A/G-C/T composite genotype did
not differ between non-familial early-onset BC (≤50 years)
versus controls (OR = 0.9 [CI 95% 0.3–2.7] p = 1.0). When
we analyzed the relationship between the composite geno-
type and BC risk within patients with familial BC history
according the number of BC cases in the family (Table 4),
we observed that the A/G-C/T composite genotype, which
includes the two risk alleles, was associated with a signifi-
cantly increased BC risk both in cases belonging to families
with two or more BC and/or OC cases and in cases
belonging to families with three or more BC and/or OC
cases, with a stronger effect of the composite genotype in
the latter group of cases "(OR = 2.6 [CI 95% 1.4-5.0]
p = 0.01) and OR = 3.6 [CI 95% 1.7-8.0] p = 0.003, respect-
ively). No association was observed in the families belong-
ing to subgroup B. In conclusion, the A/G-C/T composite
genotype produces a higher increase of BC risk in cases
with a strong family history of BC and/or OC. This finding
raises the possibility that these variants are in strong
linkage disequilibrium.
Although phase for these variants could not be deter-
mined directly from the screening data, haplotypes were
constructed from genotype data using UNPHASED soft-
ware, which uses a maximum-likelihood approach. The-
oretically, the total number of haplotypes with two SNPs
is four, but we observed only three: wildtype (rs152451-A -
rs45551636-C), rs152451-G - rs45551636-C, and rs152451-
G - rs45551636-T. The haplotype estimation suggested a
strong linkage disequilibrium between the two markers
(coefficient of linkage disequilibrium, D' = 1). When we
analyzed the haplotypes and BC risk considering the num-
ber of BC cases in the families (Table 5), we observed that
rs152451-G - rs45551636-C and rs152451-G - rs45551636-
T haplotypes were associated with a significantly increased
BC risk in the families with a strong family history of BC
and/or OC (OR = 1.6 [CI 95% 1.0-2.5] p = 0.05 and OR =
3.7 [CI 95% 1.8-7.5] p < 0.001, respectively). No association
was observed in the families belonging to subgroup B.Prediction of functional effect of PALB2 variants
The variant c.1861C > A produces the change of Pro to
Met at position 621. The multiple alignment analysis
with the PALB2 protein sequence indicates that the
amino acid in position 621 is conserved in various species.
The case-control study showed that this variant was
detected in only one of 436 cases and none of the 809
controls. This results suggest that the variant c.1861C >A
could be pathogenic. In order to predict the possible
effect of this amino acid change in the structure and
function of the PALB2 protein, we used PolyPhen-2,
SIFT and PROVEAN software, which predicted that
this variant is not likely to be pathogenic. To evaluate
protein stability, we used the i-Mutant program. The
amino acid change decreases the protein stability (-0.55
Kcal/mol). Considering the case-control study and in silico
analyses, the c.1861C > A missense mutation can be
classified as a variant of unknown significance (VUS),
or as a rare variant.
The variant c.1676A >G (p.Q559R) corresponds to a
previously-described variant (rs152415). The three patho-
genicity programs predicted that it is likely non-pathogenic.
The i-Mutant program shows that the amino acid change
slightly decreases the protein stability (-0.06 Kcal/mol).
The variant c.2993C > T (p.G998E) is also a previously-
described variant (rs45551636). The results of the bio-
informatic predictor programs indicated that it is probably
pathogenic. The results obtained with the i-Mutant pro-
gram predicted that the mutation decreases the protein
stability (-0.41 Kcal/mol). In order to analyze the possible
effect of this variant on the 3D-structure and function of
the PALB2 protein, we carried out homology modeling
using MODELLER v.9.12 (Additional file 2). The model
obtained was compared in RASMOL with the structure of
the wildtype protein, with results predicting that the
amino acid change might affect this region and then mod-
ify PALB2 function. Considering there are currently no
published functional studies, this variant could be classi-
fied as a variant of unknown significance.
Discussion
Mutations in BRCA1 and BRCA2 are associated with
susceptibility to breast and ovarian cancer. At present,
however, those mutations account for only a portion of
familial cases, and consequently there is an intensive
search for additional targets. PALB2 mutations have
been identified as BC susceptibility alleles by both case-
control and family studies [9,10,13,17,21,28-35], and are
closely associated with BRCA2. Since the initial identifi-
cation of PALB2 as a BC susceptibility gene [9], several
investigators have screened for the gene in BRCA1/2-
negative families with BC and/or women diagnosed with
early-onset BC from various ethnic backgrounds, such
as Australian [12,36], Chinese [16], German [32], Italian
Table 4 Composite genotype frequencies for rs152451 and rs45551636 PALB2 variants in BRCA1/2 negative breast cancer cases and controls
All BC cases (n = 436) Families with ≥ 2 BC and/or
OC cases (n = 273)
Families with ≥ 3 BC and/or
OC cases (n = 124)






BC cases (%) P valuea OR [95% CI] BC cases (%) P valuea OR [95% CI] BC cases (%) P valuea OR [95% CI] BC cases (%) P valuea OR [95% CI]
A/A-C/C 674 (83.3%) 351 (80.5%) - 1.0 (ref) 210 (76.9%) - 1.0 (ref) 88 (71.0%) 0 1.0 (ref) 141 (86.5%) - 1.0 (ref)
A/G-C/C 106 (13.1%) 58 (13.3%) 0.79 1.1 (0.7-1.5) 43 (15.8%) 0.18 1.3 (0.9-1.9) 23 (18.6%) 0.06 1.7 (1.0-2.7) 15 (9.2%) 0.19 0.7 (0.4-1.2)
A/G-C/T 21 (2.6%) 21 (4.8%) 0.04 1.9 (1.0-3.6) 17 (6.2%) 0.01 2.6 (1.4-5.0) 10 (8.1%) 0.003 3.6 (1.7-8.0) 4 (2.5%) 1.00 0.9 (0.3-2.7)
G/G-C/C 6 (0.7%) 4 (0.9%) 0.74 1.3 (0.4-4.6) 2 (0.7%) 1.00 1.1 (0.2-5.3) 2 (1.6%) 0.24 2.6 (0.5-12.9) 2 (1.2%) 0.63 1.6 (0.3-8.0)
G/G-C/T 2 (0.2%) 1 (0.2%) 1.00 1.0 (0.1-10.6) 0 (0.0%) - - 0 (0.0%) - - 1 (0.6%) 0.44 2.4 (0.22-26)
G/G-T/T 0 (0.0%) 1 (0.2%) - - 1 (0.4%) - - 1 (0.8%) - - 0 (0.0%) - -
BC breast cancer, OC ovarian cancer, OR odds ratio, CI confidence interval.
aFisher’s exact test.











Table 5 Haplotype effects for rs152451 and rs45551636 PALB2 variants
All BC cases (n = 436) Families with ≥ 2 BC
and/or OC cases (n = 273)
Families with ≥ 3 BC and/or
OC cases (n = 124)




BC cases (%) P valuea OR [95% CI] BC cases (%) P valuea OR [95% CI] BC cases (%) P valuea OR [95% CI] BC cases (%) P valuea OR [95% CI]
A-C 1475 (91.2%) 781 (89.6%) - 1.0 (1.0-1.0) 480 (87.9%) - 1.0 (1.0-1.0) 209 (84.3%) - 1.0 (ref) 301 (92.3%) - 1.0 (1.0-1.0)
G-C 120 (7.4%) 67 (7.7%) 0.75 1.1 (0.8-1.4) 47 (8.6%) 0.31 1.2 (0.8-1.7) 27 (10.9%) 0.05 1.6 (1.0-2.5) 20 (6.1%) 0.48 0.8 (0.5-1.3)
G-T 23 (1.4%) 24 (2.8%) 0.03 2.0 (1.1-3.5) 19 (3.5%) 0.004 2.5 (1.4-4.7) 12 (4.8%) <0.001 3.7 (1.8-7.5) 5 (1.5%) 0.80 1.1 (0.4-2.8)
BC breast cancer, OC ovarian cancer, OR odds ratio, CI confidence interval.
aFisher’s exact test.
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Polish [31], Russian [32], South African [45], and Span-
ish [46,47] populations. However, the prevalence of
PALB2 variants in the South American population had
not yet been established. In the present study, we ana-
lyzed the complete coding sequence and exon-intron
boundaries of PALB2 in Chilean BRCA1/2-negative BC
patients; nevertheless, no pathogenic mutations were
observed in the PALB2 coding sequence. Pathogenic
mutations in PALB2 are rare (varying from 0.1% to
2.7%) and vary in frequency depending on the popula-
tion [48]. No PALB2 germline mutations have been ob-
served in the geographically-confined population of
Iceland, for instance [49]. The contemporary Chilean
population stems from the admixture of Amerindian
peoples with the Spanish settlers in the 16th and 17th
centuries. Later migrations in the 19th century of other
populations (e.g., Germans, Italians, Arabs, and Croa-
tians) have had only a minor impact on the overall
population (≤4% of the total population) and are re-
stricted to the specific locations of the country where
they originally settled [50]. The relationships among
ethnicity, Amerindian admixture, genetic markers, and
socioeconomic strata have been extensively studied in
Chile [51-53]. Thus, it is probable that in the mixed
Chilean population, PALB2 is not a significant con-
tributor to BC in high-risk BC families.
We identified three sequence variants: c.1676A >G
(exon 4), c.1861C >A (exon 5), and c.2993C > T (exon 9).
With respect to c.1861C >A (exon 5), this variant is not
previously described in the literature or in the PALB2
mutation and polymorphism database (http://www.lovd.
nl/PALB2). It corresponds to a missense mutation that
produces the change of proline to methionine in the 621
position (p.P621M). It was found in only one of the 436
cases and in none of 809 controls. The patient carrier of
this variant belongs to a BRCA1/2-negative family with
three BC cases. Three sisters were screened for the vari-
ant, two with BC (diagnosed at 45 and 49 years) and the
other healthy. The c.1861C >A carrier was the sister with
BC with the earliest age of diagnosis. The bioinformatic
analyses using PolyPhen-2, SIFT and PROVEAN tools
predicted that this variant is not pathogenic, and therefore
we classified this missense mutation as a new mutation of
unknown significance.
The variants c.1676A > G (p.Q559R) and c.2993C > T
(p.G998E) correspond to previously-described variants
(rs152451 and rs45551636, respectively). These have
been described in Spanish [46], Australian [29], Asian
(Malaysian and Singaporean) [15], African–American
[54], German and Russian [32], Italian [33], Chinese
[16], and Finnish [10] populations. It is widely accepted
that according to bioinformatic analyses, the c.1676A >G
variant corresponds to a benign polymorphism whilec.2993C > T affects PALB2 protein function. In the present
study, using a case-control design, we evaluated the im-
pact of PALB2 rs152451 and rs45551636 variants in Chil-
ean women with familial and non-familial early-onset BC
who are negative for BRCA1/2 point mutations. In both
cases and controls, the allelic frequencies of both variants
were similar to those reported by Blanco et al. (2013) [46]
in a Spanish population. The MAF of rs152451 and
rs45551636 in cases (0.10 and 0.03, respectively) dif-
fered from those reported in German (0.06 and 0.03,
respectively) [32], Russian (0.06 and 0.01, respectively)
[32], and African-American (0.16 and 0.005, respectively)
[54] populations. In controls, the MAF of rs152451 and
rs45551636 were 0.09 and 0.01 respectively, differing from
those reported in the NHBLI ESP6500 database for
African-Americans (0.22 and 0.006 respectively) but simi-
lar to those reported for European-Americans (0.09 and
0.02 respectively). Therefore, MAF frequencies vary by
ethnicity. In the present study, both variants were signifi-
cantly associated with increased risk of familial BC but
not non-familial early-onset BC. On the other hand, when
we consider the number of BC cases in the family, we
found a significantly increased BC risk only in the carriers
of allele G (AG +GG) in families with 3 or more members
affected with BC and/or OC (OR = 2.0 [CI 95% 1.3-
3.2], p < 0.01). Therefore, we propose that these two
variants are associated with increased BC risk in fam-
ilies with a strong family history of BC. These results
are in agreement with those published by Antoniou
et al. [55], who concluded that the pathogenic muta-
tions in PALB2 confer an absolute risk of 58% for
those women with two or more first-degree relatives
with BC at 50 years of age, and that the risk is lower
for women with no family history of BC. This result
was confirmed by the composite genotype analysis,
suggesting that these two variants could be in linkage
disequilibrium. The haplotype analysis also suggested
strong linkage disequilibrium between the two markers.
Also, we observed that rs152451-G/rs45551636-C and
rs152451-G/rs45551636-T were associated with signifi-
cantly increased BC risk in families with a strong family
history of BC. In the literature, there are no publications
with the analysis performed in the present manuscript.
The prediction of functional effects revealed that
rs152451 is probably non-pathogenic. Nevertheless, the
region of this variant is found inside the PALB2 motif,
which interacts with chromatin [56]. This region was
not crystallized; therefore, no 3D-structure information
is available to evaluate the possible impact of this muta-
tion. However, the analyses of the amino acid change
properties (p.Q559R) lead us to propose that this variant
might have an impact on PALB2 function. Functional
analyses are needed to elucidate the effect of c.1676A >
C on PALB2 protein function, and thus to confirm the
Leyton et al. BMC Cancer  (2015) 15:30 Page 9 of 10results obtained in the case-control study. Regarding
rs45551636, the bioinformatic analysis using PolyPhen-2,
SIFT and PROVEAN tools predict that this variant is
probably pathogenic. c.2993C > T is located within the
PALB2 WD40-domain, which is involved in the inter-
action of the PALB2 protein with BRCA2 and RAD51
[56]. To analyze the effect of the amino acid change on
PALB2 protein function, the model obtained using
MODELLER v.9.12 was compared with the wildtype
PALB2 structure. We observed that the wildtype struc-
ture Gly, which is smaller and very flexible, takes part
in the loop between WD 2 and 3 repetitions. On the
other hand, in the mutated structure, glutamic acid,
which is more voluminous and negatively-charged, is
protruded towards the interior of the hydrophobic
pocket formed by WD40 repetitions resulting in an un-
usual torsion angle localized at the loop that connects
these regions. In addition, with the evidence obtained
from the bioinformatic tools, the structure-modeling
analysis strongly suggests that this variant could affect
the protein function.
Conclusions
Our data shows that PALB2 pathogenic germline muta-
tions are not present in a Chilean population, and that
rs152451 and rs45551636 are associated with increased
BC risk in BRCA1/2- negative families with a strong
family history of BC but not in non-familial early-onset
BC. These results are in agreement with Southey et al.
(2010) [12].
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